Showing results (1-10 of 382) with videos related to
Sort By:
Pageof 39
Anti-Cancer Agents in Medicinal Chemistry|October 16, 2008
Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?Andrea Bortolato, Giorgio Cozza, Stefano MoroMedicinal Research Reviews|June 16, 2009
How druggable is protein kinase CK2?Giorgio Cozza, Andrea Bortolato, Stefano MoroAnti-Cancer Agents in Medicinal Chemistry|October 6, 2009
ATP non-competitive Ser/Thr kinase inhibitors as potential anticancer agentsGiorgio Cozza, Andrea Bortolato, Ernesto Menta, et al.Expert Opinion on Drug Discovery|March 15, 2013
Designing a ligand for pharmaceutical purposesAndrea Bortolato, Stefano MoroCurrent Topics in Medicinal Chemistry|December 17, 2008
Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discoverySantiago Vilar, Giorgio Cozza, Stefano MoroBiopolymers|September 1, 2007
Elucidation of the ribonuclease A aggregation process mediated by 3D domain swapping: a computational approach reveals possible new multimeric structuresGiorgio Cozza, Stefano Moro, Giovanni GotteExpert Opinion on Therapeutic Patents|August 23, 2012
Protein kinase CK2 inhibitors: a patent reviewGiorgio Cozza, Lorenzo A Pinna, Stefano MoroMethods in Molecular Biology (Clifton, N.J.)|October 5, 2012
Molecular docking methodologiesAndrea Bortolato, Marco Fanton, Jonathan S Mason, et al.Journal of Medicinal Chemistry|February 7, 2008
Coumarin as attractive casein kinase 2 (CK2) inhibitor scaffold: an integrate approach to elucidate the putative binding motif and explain structure-activity relationshipsAdriana Chilin, Roberto Battistutta, Andrea Bortolato, et al.Chemmedchem|May 19, 2011
The role of the N-terminal domain in the regulation of the "constitutively active" conformation of protein kinase CK2α: insight from a molecular dynamics investigationAndrea Cristiani, Giorgio Costa, Giorgio Cozza, et al.Pageof 39